VICL
Vical Incorporated
NasdaqCM
People also watch:BCRXHEBLGNDNVAXXOMA
4.19-0.05 (-1.18%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close4.24
Open4.20
Bid4.17 x 200
Ask4.21 x 2000
52wk Range2.80 - 6.80
Day's Range4.13 - 4.21
Volume11,349
Avg Vol (3m)76,387
As of 10:41 AM EDT. NasdaqCM Real Time Price. Market open.
  • Zackslast month

    Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine

    Vical (VICL) presented data from a phase I/II study on its investigational genital herpes vaccine at a meeting of the American Society for Microbiology.

  • Vical, Inc. :VICL-US: Earnings Analysis: Q1, 2016 By the Numbers
    Capital Cube2 months ago

    Vical, Inc. :VICL-US: Earnings Analysis: Q1, 2016 By the Numbers

    Click here to see latest analysisVical, Inc. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Vical, Inc. – CytRx Corporation, Chimerix, Inc., Newlink Genetics Corporation, Agenus Inc., Celldex Therapeutics, Inc., Sanofi Sponsored ADR, Pfizer Inc., Merck & Co., Inc. and Bristol-Myers Squibb Company (CYTR-US, […] (Read more...) The post Vical, Inc. :VICL-US: Earnings Analysis: Q1, 2016 By the Numbers appeared first on CapitalCube.